False‐Positive Hepatitis C Virus Serology Following HeartMate 3 Left Ventricular Assist Device Implantation
- 9 November 2026
- journal article
- Published by Wiley in Artificial Organs
Abstract
Background: False‐positive hepatitis C virus (HCV) (FPHC) serology has been reported with earlier‐generation axial‐flow left ventricular assist devices (LVADs), but its frequency with the magnetically levitated HeartMate 3 and its implications for heart transplant pathways remain unknown. This study describes FPHC serology in HeartMate 3 LVAD recipients and explores associated clinical and immunological features. Methods: A retrospective, single‐center study was conducted at a specialist cardiothoracic center. All adults implanted with a HeartMate 3 LVAD between March 2018 and July 2025 with complete HCV serology before and after implantation were included. Patients developing HCV antibody positivity with negative confirmatory testing were classified as having FPHC serology. Patient demographics, blood product transfusions, liver function tests, lactate dehydrogenase, and human leukocyte antigen (HLA) sensitization were compared between groups. Results: Among 54 HeartMate 3 LVAD recipients, 10 (18.5%) developed FPHC serology after implantation. There were no significant differences between groups in age, sex, liver function tests, or lactate dehydrogenase. The number of fresh frozen plasma units transfused at implantation and the development of anti‐HLA Class I antibodies were associated with FPHC serology ( p = 0.039, p = 0.04, respectively). No significant associations were observed with red blood cell or platelet transfusions. Conclusion: FPHC serology is a clinically important phenomenon in HeartMate 3 LVAD recipients. Clinicians and patients should be aware of this phenomenon to minimize unnecessary investigations and delays to transplant candidacy assessment. Standardized confirmatory testing protocols and multicenter studies are needed to clarify the underlying immune mechanisms and their impact on post‐transplant outcomes.Keywords
This publication has 22 references indexed in Scilit:
- The Society of Thoracic Surgeons Intermacs 2024 Annual Report: Focus on Outcomes in Younger PatientsThe Annals of Thoracic Surgery, 2024
- Evolution of Mechanical Circulatory Support for advanced heart failureProgress in Cardiovascular Diseases, 2024
- Five-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized TrialJAMA, 2022
- Primary results of long‐term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist device implantsEuropean Journal of Heart Failure, 2021
- Temporal expression of cytokines and B-cell phenotypes during mechanical circulatory supportThe Journal of Thoracic and Cardiovascular Surgery, 2019
- The Neutrophil-Lymphocyte Ratio and Survival During Left Ventricular Assist Device SupportJournal of Cardiac Failure, 2019
- Ventricular assist device elicits serum natural IgG that correlates with the development of primary graft dysfunction following heart transplantationThe Journal of Heart and Lung Transplantation, 2017
- HCV false positive immunoassays in patients with LVAD: A potential trap!Journal of Clinical Virology, 2016
- HLA and MICA allosensitization patterns among patients supported by ventricular assist devicesThe Journal of Heart and Lung Transplantation, 2013
- Effect of sensitization in US heart transplant recipients bridged with a ventricular assist device: Update in a modern cohortThe Journal of Thoracic and Cardiovascular Surgery, 2011